IG17104 - Pan-European Educational Platform on Multidrug Resistant Tumours and Personalised Cancer Treatment

Multidrug resistance (MDR) affects 30 to 60% of cancer patients, causing poor quality of life and high costs for healthcare systems. Research in the MDR field is highly fragmented, and there is no professional figure of young scientists that are adequately instructed in the different disciplines, trained to have interdisciplinary and transdisciplinary views and approaches that cover preclinical and clinical research in MDR tumours in order to successfully develop diagnostic tests or new drugs for MDR tumours. This CIG aims to create this new professional figure. By exploiting the scientific excellence present in our COST Action and the experience accumulated in organising training schools, practical-theoretical courses and workshops for young scientists, the CIG aims to create a prototype for a training platform that will allow each scientist to fill the gaps in her/his scientific knowledge, and acquire a broader set of skills and expertise that will be advantageous at multiple levels. First, the young scientists will have better opportunities for employment with pharma/biotech and medical device companies as well as contract research organisations (CROs), and/or will have the tools to create start-ups and smallmedium enterprises (SMEs) that will contribute to the technological development and marketing of specific innovative products. Moreover, the training platform created during the CIG can become, over time, a permanent program for the continuous education of scientists working on MDR tumours. The program: i) will be open to researchers from both public and private institutions; ii) will include common modules, to provide a multidisciplinary and interdisciplinary view of MDR research, and also customised modules, based on the individual needs of the trainees, to grant specific and constantly updated skills and expertise; iii) will release a European certification of training recognised by the University of Turin (Italy) and by the other European Institutions involved. Moreover, the growth of a new generation of scientists with a solid scientific background and the ability to dialogue with academic institutions, companies, policy decision-makers and international regulatory agencies will help to mitigate the issue of managing patients with MDR tumours, which is of increasing social and economic burden for the healthcare systems in each country. We expect significant cultural and socio-economic benefits in the midterm (5-6 years), in line with the mission of the European Community “Beating Cancer by 2030”: 1) Create a virtuous loop of educational initiatives that put YRIs in contact with stakeholders and become the reference meetings for researchers involved in MDR management. 2) Develop the most promising inventions that are presented in the educational events into prototypes and products ready for the market, in collaboration with the stakeholders attending the events. 3) Improve the standard of care of MDR tumours thanks to the innovations generated by YRIs and properly exploited by stakeholders (clinicians, pharma/biotech and CROs).